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Objectives: In an explorative epigenome-wide association study (EWAS) to search for 
gene independent, differentially methylated DNA positions and regions (DMRs) associ-
ated with rheumatoid arthritis (RA) by studying monozygotic (MZ) twin pairs discordant 
for RA.
Methods: Genomic DNA was isolated from whole blood samples from 28 MZ twin pairs 
discordant for RA. DNA methylation was measured using the HumanMethylation450 
BeadChips. Smoking, anti-cyclic citrullinated peptide antibodies, and immunosuppressive 
treatment were included as covariates. Pathway analysis was performed using GREAT.
results: Smoking was significantly associated with hypomethylation of a DMR over-
lapping the promoter region of the RNF5 and the AGPAT1, which are implicated in 
inflammation and autoimmunity, whereas DMARD treatment induced hypermethylation 
of the same region. Additionally, the promotor region of both S100A6 and EFCAB4B 
were hypomethylated, and both genes have previously been associated with RA. We 
replicated several candidate genes identified in a previous EWAS in treatment-naïve RA 
singletons. Gene-set analysis indicated the involvement of immunologic signatures and 
cancer-related pathways in RA.
conclusion: We identified several differentially methylated regions associated with 
RA, which may represent environmental effects or consequences of the disease and 
plausible biological pathways pertinent to the pathogenesis of RA.
Keywords: rheumatoid arthritis, Dna methylation, monozygotic twins, epigenome-wide association study, 
pathway analysis
inTrODUcTiOn
Rheumatoid arthritis (RA) belongs to the group of complex autoimmune diseases mediated by 
interactions between genetic and environmental exposures. Several genome-wide association stud-
ies (GWAS) have been undertaken. Around 60 risk alleles for RA have been identified, and it is 
anticipated that currently known genetic risk factors only account for 16% of the total susceptibility 
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(1, 2). However, heritability estimates from RA twin studies vary 
considerably from 12 to 60% (3–5). In addition, there is evidence 
that only comparisons between dizygotic (DZ) and monochori-
onic monozygotic (MZ) twins are valid for inference of genetic 
heritability in classical twin studies, because dichorionic MZ 
twins are not only identical with regard to DNA sequence but 
also have a higher intraclass correlation of DNA methylation 
(DNAm) than both monochorionic MZ twins and DZ twins (6). 
Therefore, higher concordance in MZ twins may not only be due 
to a higher degree of DNA sequence similarity since molecular 
mechanisms of heritability may not be limited to the DNA 
sequence. In addition, the diverse clinical manifestations of RA 
within MZ pairs concordant for RA indicate the importance of 
non-genetic factors on the expression of the disease (7). Thus, 
there is mounting evidence that environmental factors, or sto-
chasticity, play a strong role in the etiology and expression of RA 
and that the effect may be mediated through epigenetic mecha-
nisms (6, 8). Thus, to identify environmentally induced DNAm 
changes associated with RA, we have therefore taken advantage 
of the disease-discordant identical twin design to adjust for most 
genetic effects and many non-genetic effects such as early envi-
ronment, maternal-, age-, sex-, and cohort effects. Smoking is 
the hitherto strongest environmental risk factor associated with 
RA, and in particular in the subset of RA patients possessing 
anti-citrullinated protein antibodies (ACPA) (9). In addition, 
there is strong evidence to suggest that smoking is associated 
with changes in DNAm (10), and genome-wide methylation 
data obtained on DNA from peripheral blood leukocytes sug-
gest the existence of dynamic, site-specific methylation changes 
in response to smoking, which may contribute to the extended 
risks associated with cigarette smoking that may persist many 
years after cessation (11). For these reasons we have included 
both smoking and the presence of ACPA as covariates in the data 
analysis.
Inflammatory arthritis may be associated with global genomic 
DNA hypomethylation and with specificity for some blood 
cell subpopulations that is reversed with methotrexate (MTX) 
treatment. These changes are accompanied by parallel changes 
in the levels of enzymes involved in methylation, suggesting the 
possibility of regulation at this level (12, 13). Treatment of RA 
patients with MTX has also been shown to regulate defective 
Treg cell function through demethylation of specific genetic loci 
(13). As we have investigated twins with established disease, 
who are currently or previously treated with disease-modifying 
anti-rheumatic drugs (DMARDs), we have included current 
DMARD treatment as a covariate in the data analysis. To our 
knowledge, the effect of other conventional DMARDs on 
DNAm has not been investigated. A recent study has suggested 
that DNA methylation profiling may provide a new biomarker 
of response to biologics (14), but so far, there is no evidence to 
suggest that biologics themselves have a direct effect on DNAm.
Epigenetics comprise a wide range of regulatory mechanisms 
including histone modification, miRNA expression, and DNAm. 
DNAm is under constant environmental influence, highly 
dynamic, and differs between cell-types (15). In RA, global DNA 
hypomethylation has been observed in both synovial fibro-
blasts (RASF) (12, 16–18), peripheral blood mononuclear cells 
(PBMCs), and in specific subsets of T- and B-lymphocytes that 
may be reversed by treatment (19). Several studies have focused 
on DNAm of candidate loci in PBMC from RA patients, while only 
few studies have included multiple loci or at the epigenome-wide 
level (20). We therefore performed an explorative epigenome-
wide association study (EWAS) characterizing DNAm differences 
in PMBCs from RA discordant MZ twin pairs in order to identify 
potential genetically independent DNAm marks associated 
with RA.
MaTerials anD MeThODs
Twins
Recruitment of 28 MZ twin pairs discordant for RA was done 
as previously described (4, 21). The median discordance time 
was 18 years (interquartile range 11–30 years). RA was classified 
according to the ACR 1987 criteria (22). Absence of RA was 
verified in the co-twins based on clinical examination. Zygosity 
was confirmed by genetic markers (23). DNA was extracted from 
EDTA blood and kept at −80°C until use. RA characteristics: 
females 78% mean age at disease onset 38 years, anti-CCP antibody 
positive 61%, ever smokers 69% (smoking information missing in 
14%). Sixty-eight percent were currently treated with DMARD of 
which 80% were treated with MTX, and none were treated with 
biologics or steroids. Most of the twins were in clinical remission, 
and the average CRP value was 3.9 mg/ml, range 0–29.
Dnam Measurements
Genomic DNA from peripheral blood was bisulfite converted 
using the EZ DNA methylation Kit (ZYMO research), and DNAm 
status was assessed using the Infinium 450 K HumanMethylation 
BeadChip (Illumina) according to the manufacturer’s instruc-
tions at the Norwegian Microarray Consortium in Oslo. In 
order to minimize the batch effect on intra-pair DNAm differ-
ences, co-twins were processed together on the same chip. Data 
normalization was done using the free R package minfi, which 
employs subset quantile within-array normalization (24). The 
level of DNAm was summarized by calculating the “beta” value 
defined by the Illumina’s formula as β =  M/(M +  U +  100). 
We also performed QC using minfi to calculate the detection 
p-value defined as the proportion of control probes, which have 
intensities greater than that probe on the same array. A β value 
with its assigned detection p-value >0.01 was treated as missing. 
CpGs with more than 5% missing data were dropped from the 
subsequent analysis.
To adjust for differences in cell type composition between 
co-twins, we applied a statistical algorithm integrated in minfi 
(25, 26). All downstream analyses were based on this cell type 
adjusted dataset.
statistical analysis
Identification of Differentially Methylated Positions
To identify the differentially methylated positions (DMPs) 
associated with RA, we fitted a linear regression model (27) 
to predict the mean fold change in DNAm between co-twins 
discordant for RA at each CpG site with adjustment for age, 
FigUre 1 | ra-associated DMPs. Volcano plot of detectable genome-
wide differentially methylated CpG sites in 28 monozygotic RA discordant 
twin pairs adjusted for cell type. The −log values represent the logarithm with 
base 10 of the p-value against the methylation difference (beta values) 
between the RA twin and the non-RA co-twin. Positive values indicate 
hypermethylation in the RA twin compared to the co-twin. The red dots 
represent suggestive DMPs with a nominal p-value <5 × 10−5. (a) RA twin 
versus co-twin adjusting for smoking, anti-CCP antibody, and treatment.  
(B) RA twin versus co-twin predicted by smoking adjusting for anti-CCP 
antibody and treatment. (c) RA twin versus co-twin predicted by treatment 
adjusting for smoking and anti-CCP antibody. (D) RA twin versus co-twin 
predicted by anti-CCP antibody adjusting for smoking and treatment.
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sex, smoking, anti-CCP antibody, and current DMARD treat-
ment. In this model, association with RA is indicated by an 
intercept α that is statistically different from 0 with α > 0 for 
increased and α < 0 for decreased methylation levels in diseased 
versus healthy co-twin. A slope parameter for smoking, anti-
CCP antibody, or DMARD that is statistically above or below 
0 indicates exposure associated hypermethylation (β >  0) or 
hypomethylation (β < 0). Genome-wide significance of DMPs 
was determined after correcting for multiple testing by calcu-
lating the false discovery rate (FDR) with a threshold of 0.05. 
DMPs reaching an uncorrected p-value <5 × 10−5 were defined 
as suggestive.
Identification of Differentially Methylated Regions
Differentially methylated regions (DMRs) were identified by 
the free R package bumphunter (28). First, we calculated the 
99th percentile of the smoothed βs to obtain upper and lower 
thresholds. These thresholds were then used to define hyper-
methylated or hypomethylated DMRs with smoothed peaks 
above or below the thresholds defined as putative DMRs. For 
each putative DMR identified, bumphunter calculates a sum 
statistic by taking the sum of the absolute values of all the 
smoothed βs within that region. The sum statistic was then used 
to rank all DMRs with the top-most important DMRs having the 
highest sum statistic value. To determine the statistical signifi-
cance of each putative DMR, we performed 1000 permutations 
of case–control status and estimated random DMRs for each 
permutation. Empirical genome-wide p-values were calculated 
based on family-wise error rate (FWER) that computed, for each 
observed DMR-area, the proportion of maximum area values 
per permutation that are larger than the observed area. A DMR 
reaching an empirical p-value <0.05 was defined as significant. 
We defined an observed DMR as suggestive if its area was larger 
than the smallest area in the 1000 maximum areas from each 
permutation. In addition to the empirical genome-wide p-value, 
we also estimated the empirical uncorrected p-value for a single 
DMR as the proportion of all random DMRs from 1000 per-
mutations that are larger than the area of the observed DMR. 
Multiple testing was corrected for by calculating FDR to obtain 
genome-wide significance defined as FDR <  0.05. The results 
from this latter method were consistent with the results based on 
FWER. We present the mean fold change in RA twins compared 
to co-twins adjusted for age, sex, smoking, anti-CCP antibody, 
and DMARD treatment as well as the fold change in RA twins 
predicted by each of the covariates smoking, anti-CCP antibody, 
and DMARD treatment.
gene-set analysis
We applied the DMRs as input genomic regions to Genomic 
Regions Enrichment of Annotations Tool [(GREAT) – version 
2.0] to analyze the functional significance of cis-regulatory 
regions (29). Genome Reference Consortium Human Build 
37 (GRCh37) was used as RefSeq database. GREAT was run 
against a whole genome background, and it performed both the 
binomial test over genomic regions and the hypergeometric test 
over genes to provide an accurate picture of annotation enrich-
ments for genomic regions. We only present pathways with a fold 
enrichment of at least two by either test that are also significant at 
an FDR of 0.05 by both tests.
resUlTs
Dnam in MZ Twins Discordant for ra
Since smoking is associated with both extensive changes in 
DNAm (10) and with anti-cyclic citrullinated peptide antibodies 
(anti-CCP antibodies) (9), smoking and anti-CCP antibodies 
were included as covariates. Further, MTX may elicit profound 
effects on DNAm (12). Since 68% of the patients were treated with 
DMARDs (80% with MTX), current treatment with DMARD 
was also included as a covariate. Analysis of these data revealed 
no genome-wide significant DMPs associated with RA or any of 
the covariates between co-twins (Figure 1).
TaBle 1 | The top-ranked DMrs associated with ra.
ra and covariates genomic location Distance bps nearest gene(s) in region Fold changea FDrb
ra
chr1: 153508511-153508875 364 S100A6 0.33 0.07
smokingc
chr6: 32145071-32146779 1708 RNF5 0.59 0.001
AGPAT1
chr4: 103940711-103941205 494 No nearby gene 0.51 0.082
chr12: 3862221-3862497 276 EFCAB4B 1.31 0.082
Treatmentd
chr6: 32145071-32146779 1708 RNF5 1.53 0.001
AGPAT1
chr19: 9785295-9786115 820 ZNF562 0.70 0.088
chr6: 30434072-30434552 480 No nearby gene 1.29 0.088
chr3: 146261941-146262761 820 No nearby gene 1.78 0.092
RA, rheumatoid arthritis.
aFold change between RA twin and healthy co-twin. Values below or above one reflect relative hypomethylation and hypermethylation, respectively.
bFalse discovery rated computed using permutation testing (n = 1000).
cEver smoking versus never smoking.
dCurrent treatment with disease-modifying anti-rheumatic drugs.
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regional analyses identify Differentially 
Methylated regions
It has been reported that DNAm levels are strongly correlated 
across the genome and functionally relevant findings have in 
general been associated with genomic regions rather than single 
CpGs (30). The hitherto largest EWAS in RA singletons reported 
clustering of the most significant CpGs in regions and supports 
the use of region-based statistical approaches (31). Regional 
analysis is also less prone to be affected by the technical artifacts 
associated with individual probes. We therefore also performed 
regional analyses (i.e., “bump hunting”) (28), which allow effec-
tive modeling of measurement error and biological variability. 
We identified 603 putative DMRs (“bumps”) associated with 
RA adjusted for the other covariates. The unadjusted raw beta 
values of the six top ranked DMRs are presented in Figure S1 
in Supplementary Material. In addition, we investigated the 
interaction between RA and each of the covariates smoking, 
anti-CCP antibodies, and treatment and identified 702, 570, and 
906 putative DMRs, respectively. The top ranked DMR (364 bps) 
associated with RA reached borderline genome-wide significance 
after permutation test (p < 0.07). This DMR was hypomethylated 
with a mean fold change of 0.33 and located in the promoter 
region of the S100A (S100 calcium-binding protein A6) (Table 1; 
Table S1 in Supplementary Material).
The region comprises a CpG island, and data from the Encode 
Project point to the presence of both multiple transcription 
factor binding sites, and a large DNAse hypersensitivity region. 
Furthermore, two nearby regions showed enrichment of histone 
marks, which indicate a regulatory role for this region. S100A6 
belongs to a cluster of genes on chromosome 1q21 encoding 
S100 proteins localized in the cytoplasm and/or nucleus of a wide 
range of cells.
Subsequently, we searched for DMRs associated with RA and 
predicted by any of the three covariates. The top ranked DMR 
(1708 bps) associated with RA and predicted by smoking reached 
genome-wide significance (p < 0.001). This region overlaps with 
the promoters of both RNF5 (ring finger protein 5) and AGPAT1 
(1-acylglycerol-3-phosphate O-acyltransferase 1 located in the 
class III region of the human major histocompatibility complex) 
(Figure  2; Table  1; Table S1 in Supplementary Material). This 
region also contains several transcription factor binding sites, 
DNAse hypersensitivity sites, and enrichment of histone marks 
suggesting a regulatory role for this region. Notably, this region 
also reached genome-wide significance (FDR adjusted p < 0.001) 
with treatment as predictor, but with reversed DNAm pattern to 
hypermethylation (Figure 2; Table 1; Table S1 in Supplementary 
Material). This suggests that smoking, which is the strongest 
known environmental risk factor for RA, induces hypomethyla-
tion in this promoter region and that DMARD treatment may 
reverse this. It is notable that 35 of 36 CpGs were hypomethyl-
ated in RA twin modulated by smoking, and 36 of 36 CpGs were 
hypermethylated in RA modulated by treatment (Table S2 in 
Supplementary Material).
The second and third ranked DMRs predicted by smoking 
reached borderline significance, p <  0.08 (Table 1; Table S1 in 
Supplementary Material). There are no nearby genes within the 
second DMR, but the third co-localizes with a CpG island cover-
ing parts of 5′-UTR and the first exon of EFCAB4B (EF-hand 
calcium binding domain 4B).
The second ranked DMR (p < 0.09) predicted by treatment 
included the upstream region and the first part of ZNF562 (zinc 
finger protein 562) and also harbors a CpG island and other ele-
ments suggestive of regulatory functions.
The top ranked DMR predicted by anti-CCP antibodies 
overlaps with the promotor region of two genes; CRYZ (Quinone 
oxidoreductase) and TYW3 (tRNA-yW synthesizing protein 3 
homolog), but this region did not reach genome-wide signifi-
cance (p < 0.2).
No independent population of RA discordant twin pairs was 
available for replication. We therefore compared our results 
with the hitherto largest EWAS based on peripheral blood from 
anti-CCP antibody positive and treatment naïve RA single-
tons by Liu et  al. (31). This study also corrected for cell type 
FigUre 2 | Top-ranked DMr associated with ra. The genome-wide significant differentially methylated region is located at the promoter region of AGPAT1 and 
RNF5. The top panel shows the unadjusted fold change on the y-axis (ratio of beta values, RA twin numerator, and co-twin denominator) of the 28 twin pairs. The 
middle panel displays the regression coefficients for RA (orange) and each of the covariates treatment (green), smoking (blue), and anti-CCP antibody (purple). The 
corresponding smoothed lines denote mean methylation level. The bottom panel depicts the genes and their genomic location.
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heterogeneity, age, gender, and smoking but did not investigate 
the individual effect of the covariates. These authors searched 
for DNAm associated with RA at the single-CpG-site level and 
not at the regional level, and they reduced the number of inter-
rogated CpGs from 450 to 300 K. Consequently, a comparison 
at the CpG level was not optimal, and we therefore searched for 
replication at the gene-level among the genes associated with 
DMRs predicted by RA. Among our nine top ranked DMRs, 
we identified six nearby genes suggestively associated with RA. 
These genes were also reported by Liu et  al. (Table  2; Table 
S1 in Supplementary Material), but only S100A6, C13orf38, 
and SDCCAG1 exhibited on average the same direction of 
methylation.
By contrast, the two CpGs linked to TRIM68 and C13orf38 
showed opposite directions of methylation in the study by Liu 
et al., whereas 12 of 13 and 16 of 18 CpGs in our study had the 
same direction of methylation (Table 2). Clearly, this illustrates 
the strength of the regional approach and indicates that these 
genes on average are associated with hypomethylation in RA. In 
total, 36 genes were overlapping the DMRs suggestively associ-
ated with RA in our data set. According to the study by Liu 
et al., all 36 of these genes were covered by from 1 to 7 CpGs 
reaching genome-wide significance in their study, but we can-
not compare the direction of association beyond the 6 genes 
mentioned above because Liu et al. did not investigate the effect 
of the covariates. Interestingly, the promoters of the RNF5 and 
TaBle 2 | Validation of genes nearby differentially methylated cpg sites 
identified in eWas of case–control study in singletons.
genea eWas singletons DMPs ref. # eWas MZ discordant 
twins
# 
cpgsb
average βc Bonferroni 
adj. p-valued
# 
cpgsb
Mean fold 
changee
p-valuef
S100A6 1↓ −0.010 1.3E − 07 12↓ 3↑ 0.3267 0.0678
TRIM68 1↑ 1↓ 0.0014 9.98E − 09 to 
1.60E − 07
12↓ 1↑ 0.3516 0.9517
UNC45A 4↑ 0.008375 8.21E − 10 to 
7.97E − 15
18↓ 9↑ 0.5915 0.9517
GPR19 2↑ 0.0197 4.5E − 19 to 
3.3E − 8
11↓ 6↑ 0.3930 0.9517
C13orf38 1↑ 1↓ −0.00065 2.12E − 10 to 
7.45E − 9
16↓ 2↑ 0.6598 0.9517
SDCCAG1 4↑ 0.01375 3.28E − 10 to 
1.68E − 8
2↓ 12↑ 1.8819 0.9517
aNearby genes defined by Illumina Annotation files.
bNumber of CpGs associated with the gene. Arrow down means hypomethylation, 
arrow up hypermethylation for each CpG.
cNegative β means that the average value of the implicated CpG sites is 
hypomethylated and vice versa.
dThe range of Bonferroni adjusted p-values for the CpGs.
eValues below one means that the region is hypomethylated, above one 
hypermethylated. Fold change based on CpGs annotated to this gene and not the 
DMR detected by “bump hunter.”
fFDR-adjusted p-values for region.
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AGPAT1 genes were within 100-kb distance of the identified 
DMPs in the study by Liu et al.
gene-set analysis
We then performed GSAs to explore the potential of shared bio-
logical functions and pathways among the identified DMRs. The 
603, 702, 570, and 906 putative DMRs predicted by RA, smoking, 
anti-CCP antibody, and treatment, respectively, comprised the 
input genomic regions applied to GREAT (29) to compute ontol-
ogy term enrichment and identify processes or pathways that 
are perturbed in established RA. In Table S3 in Supplementary 
Material, we present the entire list of significant ontology 
terms and pathways. Genes with promoter regions containing 
the binding site for ELK1 were enriched in RA (binomial FDR 
1.2 × 10−11) as well as in RA predicted by treatment (binomial 
FDR 2.7 × 10−15). ELK1 is a member of the E-twenty-six (ETS) 
oncogene family (32) and is an intracellular transcription factor 
of the p38MAPK signaling cascade involved in inflammation 
and tissue destruction in RA (33). It binds to three sites in the 
promoter region of tumor necrosis factor alpha (TNF-α) (34), a 
key player in the inflammation of RA. Genes upregulated in cer-
vical cancer, thyroid carcinoma, and breast tumor were enriched 
using the RA dataset, and genes upregulated in breast and ovarian 
cancer were enriched in RA predicted by smoking. Gene sets that 
represent cell states and perturbations within the immune system 
were also enriched.
A key assumption of GSA requires that all genes, a priori, have 
the same probability of appearing. In cases, where some genes are 
tested many more times than others, genes with more associated 
probes are more likely to fulfill whatever ad hoc criteria to define 
differentially methylated genes. This may cause a strong bias and 
as the Illumina 450 K BeadChip contains from 1 to 1288 probes 
per gene, this type of bias should not be neglected. However, the 
GSA presented in this study is based on regions, which may aver-
age out the number of probes per region and thereby mitigating 
this bias and reduce the number of spurious findings. Thus, we 
did not find any correlation between the significance level of 
the pathways and the number of probes per gene and the most 
significant pathways clustered around the mean number of CpGs 
per gene for the whole microarray (Figure S2 in Supplementary 
Material).
DiscUssiOn
This is the first comprehensive EWAS in MZ twins discordant 
for RA. We did not disclose DMPs associated with RA but iden-
tified one genome-wide significant DMR and several candidate 
DMRs. EWAS in MZ discordant twin pairs are particularly 
useful to detect DMRs caused by environmental or stochastic 
effects as compared with findings from case–control studies 
in singletons, which are also influenced by genetic variation. 
Some of our top ranking DMRs located in the promoter region 
of genes have previously been reported in a large EWAS on RA 
singletons (31). Thus, replication of these findings in a differ-
ent setting of MZ twin pairs discordant for RA significantly 
adds to the evidence that DNAm changes in these genes may 
mediate the effect of environmental exposures, including drug 
treatment.
The strongest signal was observed in the promoter region of 
RNF5 and AGPAT1. The protein encoded by RFN5 is an 18-kDa 
RING finger membrane-bound ubiquitin E3 ligase, which has not 
previously been associated with RA (35). It has been shown to 
decrease the level of autophagy. It has been reported previously 
that macrophages from RNF5 knock-out mice contain a greater 
number of autophagosomes surrounding bacterial pathogens 
than wild-type mice, and this RNF5 is also implicated in anti-
viral innate immune signaling (36). RNF5 has been shown to be 
downregulated in patients with established Crohn’s disease and 
ulcerative colitis (37) as well as in patients with spondyloarthritis 
and chronic gut inflammation (35). Increased expression of this 
gene has been reported in PBMCs from RA patients with active 
disease (38), and SNP genotypes of both RNF5 and AGPAT1 have 
been associated with susceptibility to type 1 diabetes (39). Thus, 
both RNF5 and AGPAT1 have been associated with inflammation 
and autoimmunity.
The S100A6 has been shown to be overexpressed in peripheral 
blood from RA patients and the expression level correlated to 
MMP3 levels (40), which accords with our finding of hypometh-
ylation in the promoter region. The active gene may therefore 
be a predictor of cartilage and bone destruction. The S100A6 is 
also overexpressed in salivary glandular epithelial cells in patients 
with Sjögren’s syndrome (41).
EFCAB4B is a Ca(2+)-binding protein that plays a key role 
in store-operated calcium entry (SOCE) in T-cells (42), and five 
different single nucleotide variations in EFCAB4B have previ-
ously been associated with RA (43). ZNF562 may be involved in 
transcriptional regulation and has to our knowledge not previ-
ously been associated with RA.
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Although the DMR nearby CRYZ and TYWS did not reach 
genome-wide significance in our study, DMPs in the promotor 
regions of these genes did reach genome-wide significance in 
the study by Liu et al. (31) DMRs overlapping these genes have 
previously been related to response to biologics (44), and the 
genes have been associated with both inflammation and Type 2 
diabetes (45).
None of the genes nearby our top ranked DMRs were among 
the five different genes that according to Liu. et  al. (31) may 
mediate their effect through changes in DNAm. If the DNAm 
differences predominantly mediate genetic effects, we would not 
expect to find these DNAm differences within our RA discordant 
MZ twin pairs. Hence, this discordance with Liu et al. indirectly 
supports that the effect of these polymorphisms are mediated via 
DNAm variation.
Previous studies by Nile et al. and Ishida et al. reported hypo-
methylation of single, but distinctive, CpG motifs in the promoter 
region of interleukin-6 in genomic DNA from PBMCs, which 
were associated with RA (46, 47). However, both the number 
and position of CpG motifs in the IL-6 promoter region differed 
between the two populations and neither of the two distinct motifs 
were among the interrogated sites on the 450 K Illumina assay. 
Among the other five interrogated CpG motifs in the promoter 
region of IL-6 on the 450 K assay, none were associated with RA 
in our study in accordance with the findings in the UK (46) and 
the Japanese studies (47).
In a study by Liao et al., 10 CpG motifs in the promoter region 
of CD40L on the X chromosome from CD4+ T cells were found 
to be hypomethylated in female RA patients and correlated with 
mRNA expression (48). We found no aberrant methylation pat-
tern when analyzing the same promoter region separately for 
male and female twin pairs. This discrepancy may be explained 
by genetic variation between cases and controls in the Chinese 
study as well as differences in ethnicity, interrogated motifs, and 
cell type specificity. Furthermore, differences in treatment may 
also contribute to divergence from their results.
Genes upregulated in poorly differentiated thyroid carcinoma 
compared to normal thyroid tissue were enriched using the RA 
dataset. Autoimmune thyroid diseases (AITD) are associated 
with RA, and several studies have shown an association of AITD 
and papillary thyroid cancer (49). A higher prevalence of papil-
lary thyroid cancers has been reported in RA patients (50) and 
other systemic autoimmune disorders including Sjøgrens syn-
drome (51, 52). Although the increased malignancy risk in RA is 
primarily associated with lymphomas and lung cancer (53–55), 
our GSA also revealed enrichment of genes upregulated in breast 
cancer and ovarian cancer. Even though there in no evidence of 
a direct association of RA with these cancers, it has previously 
been emphasized that the destructive process of RA may share 
features with neoplastic tissue. Thus, RA synoviocytes can grow 
under anchorage-independent conditions with defective contact 
inhibition, and synovial dedifferentiation and angiogenesis and 
mutations in the p53 tumor suppressor gene have been described 
in synovial tissue (56). From an epigenetic viewpoint, cancer and 
RA are characterized by genome-wide hypomethylation (12, 57, 
58), and the demonstration of pathways shared by cancer and 
RA may provide new insights into disease-overlapping aspects 
of these two disease categories and might help to explain the 
invasive aspects of the diseases.
Although our study has taken advantage of the efficient 
MZ co-twin control method with adjustment for important 
confounders, some limitations should be considered. Thus, 
mosaicism for de novo mutations, retrotranspositions, indels, 
duplications, and chromosomal rearrangements may play a role 
in MZ twin discordance. In addition, copy number variants 
(CNVs) may manifest as DNAm changes, as suggested in one 
study on autism (59), although CNVs in general seem to have 
little impact on bead-array-based measures of DNAm (60). Also, 
we can not exclude the possibility of residual confounding due to 
cell type heterogeneity.
The inflammatory process in RA is systemic and may beside 
joints target a variety of extra-articular sites. While the etiology 
of RA remains elusive, there is robust evidence that T cells, B 
cells, and proinflammatory cytokine and chemokine networks 
are core pathogenetic mediators in RA. However, additional 
peripheral blood cells are implicated as well including innate 
effector cells like macrophages, mast cells, dendritic cells, and 
natural killer cells (61). Synovitis is caused by activation of 
these subpopulation of mononuclear cells in conjunction with 
granulocytes and angiogenesis (62). Although epigenetic studies 
at the level of specific cellular types seem attractive, it is worth 
considering that in a cross-sectional design like the present, there 
is an inherent risk that demethylation changes co-occurring in 
different cell subpopulations may go unrecognized by focusing 
on one particular cell type or that the significance of single cell 
type methylation changes are overestimated. Accordingly, in this 
exploratory study, which relies on a strong experimental design 
including MZ twins who are discordant for RA, we found it 
appropriate to study epigenetic marks in whole PBMCs. Despite 
the risk of a “dilution effect” by normally methylated subsets of 
cells, demethylation alterations were actually detected in several 
candidate regions reaching genome-wide significance at p levels 
between 0.001 and 0.1. These effect sizes accord well with the so 
far largest EWAS on singletons, which also relied on DNA from 
PMBC (31).
We have not done technical verification, but investigator-
initiated studies on the validity of the 450 K Illumina assay have 
shown robust results when compared to DNAm measurement 
based on sequencing (63, 64). Furthermore, we have minimized 
batch effects because samples from cases and controls were 
processed simultaneously and have been placed on the same 
plates. In order to reduce biological variation, blood samples 
were drawn simultaneously from either twin in each. Last but 
not least, since we are dealing with MZ discordant twin pairs, the 
effects of genetic variants affecting probe binding or read-out are 
indistinguishable between cases and controls.
Although, we did not collect samples for quantification of 
mRNA in whole blood, our results accord with previously pub-
lished gene expression studies on the RNF5 and the S100A6 in 
peripheral blood from RA patients and patients with Sjögren’s 
syndrome (38, 40, 41).
We also considered treatment as a source of epigenetic 
modification. However, our study is based on a population of 
RA twins with different disease profiles, which may influence 
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our findings (65). Notably, all our RA discordant twin pairs 
underwent standardized clinical examination, and we therefore 
have optimally validated information of treatment at the time of 
blood sampling. Thus, this is in fact the first study to address the 
effect of treatment in a EWAS. It may be argued that the study 
is underpowered because only 68% of the cases were currently 
treated with a DMARD. Nevertheless, we observed a significant 
genome-wide effect of treatment on DMAm, and interest-
ingly that the effect of smoking on DNAm in RA was partially 
antagonized by DMARD treatment. Concerning power, it has 
previously been estimated that 15 MZ disease-discordant twin 
pairs have reasonable power to detect disease-associated DMRs 
(66). Our disease-discordant MZ twin design provides a perfect 
match for genetics, maternal, and cohort effects as well as age 
and sex. But in addition, we have also been able to adjust for 
important covariates known to influence DNAm, e.g., smoking 
and treatment, which further increases the power of our study.
By focusing on MZ twins, the case co-twin design is especially 
useful in epigenetic studies as one of the main tasks in these stud-
ies is to find environmental exposures that are associated with 
the observed epigenetic changes linked to disease status. In our 
model, we have measured the intra-pair differential DNAm as 
a function of environmental exposure, providing adjustment 
for confounding factors as fixed effects and taking into account 
random effects such as batch effect, arrangement of samples on 
the array, etc. The effects of age and sex are matched out in the 
co-twin design; however in epigenetic studies, this argument 
does not hold because within-twin pair difference in epigenetic 
measurement can be higher in old than in young twin pairs, and 
for some specific sites within-twin pairs, epigenetic difference 
can differ according to sex. Therefore, age and sex were included 
as pair-specific covariates with fixed effects and their effects 
adjusted (27).
This is a cross-sectional study including cases with already 
established disease implying that the epigenetic changes may 
reflect both cause and effect of chronic inflammation. Yet, 
secondary effects may help to further elucidate the RA patho-
genesis and lead to discovery of early diagnostic and prognostic 
markers. Furthermore, individual epigenetic signatures that 
remain stable over time have been described (67) and hold 
promise for use at the level of the individual by analogy with 
genotypes. Such regions can be considered as candidates for 
assessment of DNAm associations with disease, whereas those 
that are particularly labile may be relevant when assessing 
epigenetic marks of, e.g., treatment effects. Further epigenetic 
studies replicating our findings in samples collected in early 
life and before clinical disease onset may help to resolve these 
issues.
In conclusion, this exploratory EWAS on a well-characterized 
sample of MZ twin pairs discordant for RA has identified candi-
date regions and plausible biological pathways pertinent to the 
pathogenesis of RA, which are not explained by genetic varia-
tion. Our study also strongly suggests that there is an interaction 
between important covariates, DNAm, and RA. The present data 
are available for application in other levels of, e.g., genomics, 
transcriptomic, and proteomics to enhance meta-dimensional 
analyses to achieve a more detailed comprehension of the RA 
disease pathways (68).
eThics
The study was approved by all the regional scientific ethics com-
mittees in Denmark (Projekt ID: S-20070088) and the Danish 
Data Protection board (J. nr. 2007-41-0747). We obtained 
informed written consent from all participants in the study.
aUThOr cOnTriBUTiOns
AS conceived the study. QT, KG, RL, LC, and AS performed the 
analysis and interpretation of the data. GH, CN, LC, RL, KG, and 
KK contributed reagents/materials/analysis tools. AS, QT, KG, 
RL, LC, and PJ prepared the manuscript. All the authors read 
and approved the manuscript.
acKnOWleDgMenTs
We thank Henriette Cederholm for help with the logistics and 
interviews, Susanne Knudsen for the establishment of a blood 
and DNA repository, and Lars Hvidberg for data management.
FUnDing
This work was supported by The Danish Rheumatism Association 
and The KID foundation.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online 
at http://journal.frontiersin.org/article/10.3389/fimmu.2016. 
00510/full#supplementary-material.
reFerences
1. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. 
Genome-wide association study meta-analysis identifies seven new rheuma-
toid arthritis risk loci. Nat Genet (2010) 42(6):508–14. doi:10.1038/ng.582 
2. Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheu-
matoid arthritis. Nat Rev Rheumatol (2013) 9(3):141–53. doi:10.1038/
nrrheum.2012.237 
3. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, 
et  al. Characterizing the quantitative genetic contribution to rheumatoid 
arthritis using data from twins. Arthritis Rheum (2000) 43(1):30–7. 
doi:10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B 
4. Svendsen AJ, Kyvik KO, Houen G, Junker P, Christensen K, Christiansen 
L, et  al. On the origin of rheumatoid arthritis: the impact of environment 
and genes – a population based twin study. PLoS One (2013) 8(2):e57304. 
doi:10.1371/journal.pone.0057304 
5. Haj Hensvold A, Magnusson PKE, Joshua V, Hansson M, Israelsson L, 
Ferreira R, et  al. Environmental and genetic factors in the development of 
anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheuma-
toid arthritis: an epidemiological investigation in twins. Ann Rheum Dis  
(2015) 74(2):375–80. doi:10.1136/annrheumdis-2013-203947 
6. Kaminsky ZA, Tang T, Wang SC, Ptak C, Oh GH, Wong AH, et  al. DNA 
methylation profiles in monozygotic and dizygotic twins. Nat Genet (2009) 
41(2):240–5. doi:10.1038/ng.286 
9Svendsen et al. Epigenetics in RA
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 510
7. MacGregor AJ, Bamber S, Carthy D, Vencovsky J, Mageed RA, Ollier WE, 
et al. Heterogeneity of disease phenotype in monozygotic twins concordant 
for rheumatoid arthritis. Br J Rheumatol (1995) 34:215–20. doi:10.1093/
rheumatology/34.3.215 
8. Petronis A. Epigenetics as a unifying principle in the aetiology of com-
plex traits and diseases. Nature (2010) 465(7299):721–7. doi:10.1038/ 
nature09230 
9. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet (2009) 
373(9664):659–72. doi:10.1016/S0140-6736(09)60008-8 
10. Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. 
Tobacco smoking leads to extensive genome-wide changes in DNA methyla-
tion. PLoS One (2013) 8(5):e63812. doi:10.1371/journal.pone.0063812 
11. Wan ES, Qiu W, Baccarelli A, Carey VJ, Bacherman H, Rennard SI, et  al. 
Cigarette smoking behaviors and time since quitting are associated with 
differential DNA methylation across the human genome. Hum Mol Genet 
(2012) 21(13):3073–82. doi:10.1093/hmg/dds135 
12. Kim YI, Logan JW, Mason JB, Roubenoff R. DNA hypomethylation in 
inflammatory arthritis: reversal with methotrexate. J Lab Clin Med (1996) 
128(2):165–72. doi:10.1016/S0022-2143(96)90008-6 
13. Cribbs AP, Kennedy A, Penn H, Amjadi P, Green P, Read JE, et al. Methotrexate 
restores regulatory T cell function through demethylation of the FoxP3 
upstream enhancer in patients with rheumatoid arthritis. Arthritis Rheumatol 
(2015) 67(5):1182–92. doi:10.1002/art.39031 
14. Plant D, Webster A, Nair N, Oliver J, Smith SL, Eyre S, et  al. Differential 
methylation as a biomarker of response to etanercept in patients with rheu-
matoid arthritis. Arthritis Rheumatol (2016) 68(6):1353–60. doi:10.1002/art. 
39590 
15. Ziller MJ, Gu H, Muller F, Donaghey J, Tsai LTY, Kohlbacher O, et al. Charting 
a dynamic DNA methylation landscape of the human genome. Nature (2013) 
500(7463):477–81. doi:10.1038/nature12433 
16. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethyl-
ation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum (2009) 
60(12):3613–22. doi:10.1002/art.25018 
17. Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS. DNA methylome 
signature in rheumatoid arthritis. Ann Rheum Dis (2013) 72(1):110–7. 
doi:10.1136/annrheumdis-2012-201526 
18. Liu C-C, Fang T-J, Ou T-T, Wu C-C, Li R-N, Lin Y-C, et al. Global DNA meth-
ylation, DNMT1, and MBD2 in patients with rheumatoid arthritis. Immunol 
Lett (2011) 135(1–2):96–9. doi:10.1016/j.imlet.2010.10.003 
19. de Andres MC, Perez-Pampin E, Calaza M, Santaclara FJ, Ortea I, Gomez-
Reino JJ, et al. Assessment of global DNA methylation in peripheral blood cell 
subpopulations of early rheumatoid arthritis before and after methotrexate. 
Arthritis Res Ther (2015) 17(1):1–9. doi:10.1186/s13075-015-0748-5 
20. Bottini N, Firestein GS. Epigenetics in rheumatoid arthritis: a primer for 
rheumatologists. Curr Rheumatol Rep (2013) 15(11):372. doi:10.1007/
s11926-013-0372-9 
21. Svendsen AJ, Holm NV, Kyvik K, Petersen PH, Junker P. Relative importance 
of genetic effects in rheumatoid arthritis: historical cohort study of Danish 
nationwide twin population. BMJ (2002) 324(7332):264–6. doi:10.1136/
bmj.324.7332.264 
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. 
The American Rheumatism Association 1987 revised criteria for the classifica-
tion of rheumatoid arthritis. Arthritis Rheum (1988) 31:315–24. doi:10.1002/
art.1780310302 
23. Christiansen L, Frederiksen H, Schousboe K, Skytthe A, von Wurmb-
Schwark N, Christensen K, et  al. Age- and sex-differences in the validity 
of questionnaire-based zygosity in twins. Twin Res (2003) 6(4):275–8. 
doi:10.1375/136905203322296610 
24. Maksimovic J, Gordon L, Oshlack A. SWAN: subset-quantile within array 
normalization for illumina infinium HumanMethylation450 BeadChips. 
Genome Biol (2012) 13(6):R44. doi:10.1186/gb-2012-13-6-r44 
25. Houseman EA, Christensen BC, Yeh RF, Marsit CJ, Karagas MR, Wrensch 
M, et al. Model-based clustering of DNA methylation array data: a recursive- 
partitioning algorithm for high-dimensional data arising as a mixture of beta 
distributions. BMC Bioinformatics (2008) 9:365. doi:10.1186/1471-2105- 
9-365 
26. Houseman EA, Molitor J, Marsit CJ. Reference-free cell mixture adjustments 
in analysis of DNA methylation data. Bioinformatics (2014) 30(10):1431–9. 
doi:10.1093/bioinformatics/btu029 
27. Tan Q, Christiansen L, von Bornemann Hjelmborg J, Christensen K. Twin 
methodology in epigenetic studies. J Exp Biol (2015) 218(Pt 1):134–9. 
doi:10.1242/jeb.107151 
28. Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP, et al. Bump 
hunting to identify differentially methylated regions in epigenetic epidemiol-
ogy studies. Int J Epidemiol (2012) 41(1):200–9. doi:10.1093/ije/dyr238 
29. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT 
improves functional interpretation of cis-regulatory regions. Nat Biotechnol 
(2010) 28(5):495–501. doi:10.1038/nbt.1630 
30. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, et al. DNA 
methylation profiling of human chromosomes 6, 20 and 22. Nat Genet (2006) 
38(12):1378–85. doi:10.1038/ng1909 
31. Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, 
et  al. Epigenome-wide association data implicate DNA methylation as an 
intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol (2013) 
31(2):142–7. doi:10.1038/nbt.2487 
32. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell 
Biol (2001) 2(11):827–37. doi:10.1038/35099076 
33. Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase 
(MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis (2008) 67(7):909–
16. doi:10.1136/ard.2007.074278 
34. Tsai EY, Falvo JV, Tsytsykova AV, Barczak AK, Reimold AM, Glimcher 
LH, et  al. A lipopolysaccharide-specific enhancer complex involving ets, 
Elk-1, Sp1, and CREB binding protein and p300 is recruited to the tumor 
necrosis factor alpha promoter in vivo. Mol Cell Biol (2000) 20(16):6084–94. 
doi:10.1128/MCB.20.16.6084-6094.2000 
35. Laukens D, Peeters H, Cruyssen BV, Boonefaes T, Elewaut D, De Keyser F, et al. 
Altered gut transcriptome in spondyloarthropathy. Ann Rheum Dis (2006) 
65(10):1293–300. doi:10.1136/ard.2005.047738 
36. Kuang E, Okumura CYM, Sheffy-Levin S, Varsano T, Shu VC-W, Qi J, et al. 
Regulation of ATG4B stability by RNF5 limits basal levels of autophagy 
and influences susceptibility to bacterial infection. PLoS Genet (2012) 
8(10):e1003007. doi:10.1371/journal.pgen.1003007 
37. Dooley TP, Curto EV, Reddy SP, Davis RL, Lambert GW, Wilborn TW, et al. 
Regulation of gene expression in inflammatory bowel disease and correlation 
with IBD drugs. Screening by DNA microarrays. Inflamm Bowel Dis (2004) 
10(1):1–14. doi:10.1097/00054725-200401000-00001 
38. Edwards CJ, Feldman JL, Beech J, Shields KM, Stover JA, Trepicchio WL, 
et al. Molecular profile of peripheral blood mononuclear cells from patients 
with rheumatoid arthritis. Mol Med (2007) 13(1–2):40–58. doi:10.2119/ 
2006-000056.Edwards 
39. McKinnon E, Morahan G, Nolan D, James I; Diabetes Genetics Consortium. 
Association of MHC SNP genotype with susceptibility to type 1 diabetes: a 
modified survival approach. Diabetes Obes Metab (2009) 11(Suppl 1):92–100. 
doi:10.1111/j.1463-1326.2008.01009.x 
40. Lee HM, Sugino H, Aoki C, Murakami M, Matsutani T, Ochi T, et  al. 
Correlations between S100 gene expression levels and the local and systemic 
inflammatory markers (matrix metalloproteinase-3, MMP3; erythrocyte 
sedimentation rate, ESR) in rheumatoid arthritis patients [abstract]. Arthritis 
Rheum (2011) 63(Suppl 10):1925. 
41. Steinfeld S, Rommes S, Francois C, Decaestecker C, Maho A, Appelboom T, 
et  al. Big prolactin 60  kDa is overexpressed in salivary glandular epithelial 
cells from patients with Sjogren’s syndrome. Lab Invest (2000) 80(2):239–47. 
doi:10.1038/labinvest.3780027 
42. Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev 
Immunol (2007) 7(9):690–702. doi:10.1038/nri2152 
43. Mitsunaga S, Hosomichi K, Okudaira Y, Nakaoka H, Kunii N, Suzuki Y, et al. 
Exome sequencing identifies novel rheumatoid arthritis-susceptible variants 
in the BTNL2. J Hum Genet (2013) 58(4):210–5. doi:10.1038/jhg.2013.2 
44. Webster A, Plant D, Eyre S, Wilson G, Morgan A, Isaacs J, et al. OP0257 differ-
ential DNA methylation related to response to adalimumab and etanercept in 
patients with rheumatoid arthritis. Ann Rheum Dis (2014) 73(Suppl 2):158–9. 
doi:10.1136/annrheumdis-2014-eular.4104 
45. Qi Q, Menzaghi C, Smith S, Liang L, de Rekeneire N, Garcia ME, et al. Genome-
wide association analysis identifies TYW3/CRYZ and NDST4 loci associated 
with circulating resistin levels. Hum Mol Genet (2012) 21(21):4774–80. 
doi:10.1093/hmg/dds300 
46. Nile CJ, Read RC, Akil M, Duff GW, Wilson AG. Methylation status of a 
single CpG site in the IL6 promoter is related to IL6 messenger RNA levels 
10
Svendsen et al. Epigenetics in RA
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 510
and rheumatoid arthritis. Arthritis Rheum (2008) 58(9):2686–93. doi:10.1002/
art.23758 
47. Ishida K, Kobayashi T, Ito S, Komatsu Y, Yokoyama T, Okada M, et  al. 
Interleukin-6 gene promoter methylation in rheumatoid arthritis and 
chronic periodontitis. J Periodontol (2012) 83(7):917–25. doi:10.1902/jop. 
2011.110356 
48. Liao J, Liang G, Xie S, Zhao H, Zuo X, Li F, et al. CD40L demethylation in 
CD4+ T cells from women with rheumatoid arthritis. Clin Immunol (2012) 
145(1):13–8. doi:10.1016/j.clim.2012.07.006 
49. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. 
Autoimmune thyroid disorders. Autoimmun Rev (2015) 14(2):174–80. 
doi:10.1016/j.autrev.2014.10.016  
50. Lee Y-A, Lee S-H, Song R, Yang H-I, Hong S-J, Min K. Higher prevalence of 
coexisting papillary thyroid cancer as well as autoimmune thyroid diseases 
in patients with rheumatoid arthritis [abstract]. Arthritis Rheum (2010) 
62(Suppl 10):1038.
51. Weng M-Y, Huang Y-T, Liu M-F, Lu T-H. Incidence of cancer in a nationwide 
population cohort of 7852 patients with primary Sjögren’s syndrome in 
Taiwan. Ann Rheum Dis (2012) 71(4):524–7. doi:10.1136/annrheumdis-2011- 
200402 
52. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjögren’s syndrome and malig-
nancy risk: a systematic review and meta-analysis. Ann Rheum Dis (2014) 
73(6):1151–6. doi:10.1136/annrheumdis-2013-203305 
53. Smitten A, Simon T, Hochberg M, Suissa S. A meta-analysis of the incidence 
of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 
(2008) 10(2):R45. doi:10.1186/ar2404 
54. Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, et al. Risk of 
cancer in patients receiving non-biologic disease-modifying therapy for rheu-
matoid arthritis compared with the UK general population. Rheumatology 
(2013) 52(1):91–8. doi:10.1093/rheumatology/kes350 
55. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller H, Olsen JH. 
Rheumatoid arthritis and cancer risk. Eur J Cancer (1996) 32(10):1753–7. 
doi:10.1016/0959-8049(96)00210-9 
56. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature (2003) 
423(6937):356–61. doi:10.1038/nature01661 
57. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics (2009) 
1(2):239–59. doi:10.2217/epi.09.33 
58. Karouzakis E, Gay RE, Gay S, Neidhart M. Epigenetic control in rheuma-
toid arthritis synovial fibroblasts. Nat Rev Rheumatol (2009) 5(5):266–72. 
doi:10.1038/nrrheum.2009.55
59. Ladd-Acosta C, Hansen KD, Briem E, Fallin MD, Kaufmann WE, Feinberg AP. 
Common DNA methylation alterations in multiple brain regions in autism. 
Mol Psychiatry (2014) 19:862–71. doi:10.1038/mp.2013.114 
60. Houseman EA, Christensen BC, Karagas MR, Wrensch MR, Nelson HH, 
Wiemels JL, et al. Copy number variation has little impact on bead-array-based 
measures of DNA methylation. Bioinformatics (2009) 25(16):1999–2005. 
doi:10.1093/bioinformatics/btp364 
61. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 
(2011) 365(23):2205–19. doi:10.1056/NEJMra1004965 
62. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev 
Drug Discov (2003) 2(6):473–88. doi:10.1038/nrd1109 
63. Roessler J, Ammerpohl O, Gutwein J, Hasemeier B, Anwar S, Kreipe H, 
et  al. Quantitative cross-validation and content analysis of the 450k DNA 
methylation array from Illumina, Inc. BMC Res Notes (2012) 5(1):210. 
doi:10.1186/1756-0500-5-210 
64. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. 
Evaluation of the infinium methylation 450K technology. Epigenomics (2011) 
3(6):771–84. doi:10.2217/epi.11.105 
65. Nakano K, Boyle DL, Firestein GS. Regulation of DNA methylation in 
rheumatoid arthritis synoviocytes. J Immunol (2013) 190(3):1297–303. 
doi:10.4049/jimmunol.1202572 
66. Kaminsky Z, Petronis A, Wang SC, Levine B, Ghaffar O, Floden D, et  al. 
Epigenetics of personality traits: an illustrative study of identical twins 
discordant for risk-taking behavior. Twin Res Hum Genet (2008) 11(1):1–11. 
doi:10.1375/twin.11.1.1 
67. Feinberg AP, Irizarry RA, Fradin D, Aryee MJ, Murakami P, Aspelund T, 
et al. Personalized epigenomic signatures that are stable over time and covary 
with body mass index. Sci Transl Med (2010) 2(49):49ra67. doi:10.1126/
scitranslmed.3001262 
68. Ritchie MD, Holzinger ER, Li R, Pendergrass SA, Kim D. Methods of integrat-
ing data to uncover genotype-phenotype interactions. Nat Rev Genet (2015) 
16(2):85–97. doi:10.1038/nrg3868 
Conflict of Interest Statement: This is an investigator initiated study, and the 
funding source had no role in design and conduct of the study; collection, 
management, analysis, and interpretation of the data; and preparation, review, or 
approval of the manuscript. The authors have declared that no competing interests 
exist.
Copyright © 2016 Svendsen, Gervin, Lyle, Christiansen, Kyvik, Junker, Nielsen, 
Houen and Tan. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
